
HOPA 2025: Understanding the Recent Changes for 505(b)(2) Drugs and Reimbursement
For oncology pharmacists, understanding the 505(b)(2) approval pathway and its implications is necessary to effectively navigate the challenges 505(b)(2) drugs are creating for infusion center pharmacies, explained Scott Soefje, PharmD, MBA, BCOP, FCCP, …